Our Pricing

Understanding 1.7mg Wegovy Price and Prescription Access in the UK

The 1.7mg Wegovy price at Cured Pharmacy starts from £149.00, representing the cheapest UK price for this maintenance dose of semaglutide weight loss treatment. As a UK-registered online pharmacy (GPhC 9012511), we provide transparent upfront pricing with no hidden fees, combined with a clinical consultation completed in under three minutes by our registered prescribers. This guide explains the cost structure, dosing protocol, and prescription pathway for accessing Wegovy 1.7mg in the UK.

What Determines the 1.7mg Wegovy Price in the UK?

The 1.7mg Wegovy price reflects several factors including the cost of the active pharmaceutical ingredient semaglutide, manufacturing standards required for GLP-1 receptor agonist biologics, and the UK regulatory pathway through the MHRA. At Cured Pharmacy, our pricing of £149.00 includes the medication, clinical assessment by a UK-registered prescriber, and dispensing by our superintendent pharmacist Tarun Kumar (GPhC 2233073). Unlike some providers who add consultation fees separately, our transparent model shows the total cost before you begin the assessment[1].

The 1.7mg dose represents the penultimate step in the Wegovy titration schedule, typically reached after 16 weeks of gradual dose escalation from the 0.25mg starting dose. This structured approach, validated in the STEP clinical trial programme, minimises gastrointestinal side effects whilst optimising weight loss outcomes. In the STEP 1 trial, participants using semaglutide 2.4mg (the maintenance dose following 1.7mg) achieved an average weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo[2].

When comparing the 1.7mg Wegovy price across UK pharmacies, it's essential to verify what's included in the quoted cost. At Cured Pharmacy, the £149.00 price covers a four-week supply of pre-filled pens, with no additional charges for the prescriber consultation or standard delivery. New patients can Save £20 using code Weightlossnew on their first order, reducing the initial investment whilst maintaining access to genuine UK-licensed medication.

How the 1.7mg Wegovy Price Fits Within Your Treatment Journey

Understanding the 1.7mg Wegovy price requires context within the full dosing schedule. Wegovy treatment begins at 0.25mg once weekly for four weeks, then escalates through 0.5mg, 1mg, and 1.7mg doses before reaching the 2.4mg maintenance dose. Each escalation step lasts four weeks, meaning you'll reach the 1.7mg dose at week 13 of treatment, subject to prescriber approval at each stage[3].

The cost structure at Cured Pharmacy reflects this titration pathway. Whilst the 1.7mg Wegovy price is £149.00 per four-week supply, earlier doses in the escalation schedule are priced proportionally to support sustained treatment adherence. Our UK-registered clinical team reviews your progress at each dose transition, ensuring the escalation remains appropriate based on your weight loss response and tolerability profile. This individualised approach aligns with NICE guidance on GLP-1 receptor agonist prescribing for weight management.

Patients typically spend four weeks at the 1.7mg dose before transitioning to the 2.4mg maintenance dose, where most remain for the duration of their treatment programme. Clinical data from the STEP trials showed that participants who completed the full dose escalation experienced better tolerability outcomes compared to those who escalated more rapidly, highlighting the importance of this structured pathway despite the associated costs[2].

Budgeting for Long-Term Wegovy Treatment

Weight management with Wegovy represents a long-term commitment, with clinical trials demonstrating optimal outcomes when treatment continues for at least 68 weeks. When planning your budget, consider that after reaching the 2.4mg maintenance dose at week 17, you'll continue at this dose for the remainder of your treatment journey. The 1.7mg Wegovy price of £149.00 applies for just one month within this timeline, making it a transitional cost rather than an ongoing expense. Our pharmacy offers competitive pricing across all Wegovy doses to support treatment continuity without financial barriers.

Comparing the 1.7mg Wegovy Price with Alternative Weight Loss Treatments

When evaluating the 1.7mg Wegovy price against alternatives, consider both the pharmacological mechanism and clinical efficacy data. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the incretin hormone to reduce appetite and slow gastric emptying. Mounjaro (tirzepatide), available from £149.00 at Cured Pharmacy, combines GLP-1 and GIP receptor agonism, with SURPASS trial data showing marginally greater weight loss in head-to-head comparisons[4].

The 1.7mg Wegovy price sits within a competitive UK market for prescription weight loss medications. Saxenda (liraglutide), an earlier-generation GLP-1 agonist requiring daily rather than weekly injections, starts from £149.00 but demonstrated lower average weight loss in clinical trials compared to semaglutide. For patients seeking non-injection options, oral treatments like Orlistat (from £149.00) and Mysimba (from £149.00) work through different mechanisms with distinct efficacy profiles. Your prescriber will recommend the most clinically appropriate option based on your medical history and weight loss goals.

Cost-effectiveness extends beyond the upfront 1.7mg Wegovy price to include factors like injection frequency, side effect profile, and expected weight loss magnitude. Wegovy's once-weekly administration offers convenience advantages over daily injections, potentially improving long-term adherence. The STEP trial programme enrolled over 4,500 participants across multiple studies, providing robust evidence for semaglutide's efficacy and safety profile in diverse patient populations[2].

Accessing the 1.7mg Wegovy Price Through Online Prescription at Cured Pharmacy

Obtaining Wegovy at our transparent 1.7mg Wegovy price of £149.00 begins with a three-minute online clinical assessment. Our digital consultation, designed by UK-registered prescribers, gathers essential medical history including current medications, cardiovascular risk factors, and previous weight loss attempts. This information enables our clinical team to determine whether Wegovy represents a safe and appropriate treatment option for your individual circumstances, in accordance with MHRA prescribing guidelines[1].

The assessment covers contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease. Patients with type 2 diabetes require particular consideration, as semaglutide may affect blood glucose control and necessitate adjustment of existing diabetes medications. Our prescribers review these factors before approving your Wegovy prescription, ensuring clinical safety takes precedence over commercial considerations.

Once approved, your Wegovy 1.7mg prescription is dispensed by our GPhC-registered pharmacy team and dispatched via next-day courier in 100% discreet packaging. The medication arrives as genuine UK-licensed Wegovy pre-filled pens, manufactured by Novo Nordisk to pharmaceutical-grade standards. Each pen contains four doses of 1.7mg semaglutide for once-weekly subcutaneous injection, with comprehensive patient information leaflets included to support safe self-administration.

Clinical Monitoring While Taking 1.7mg Wegovy

Patients using the 1.7mg Wegovy dose should maintain regular contact with their prescriber to monitor treatment response and manage any emerging side effects. Common adverse effects at this dose include nausea, diarrhoea, and constipation, typically mild to moderate in severity and diminishing over time. Our clinical team remains available via phone (+44 116 4646009) to address concerns and provide guidance on symptom management. Serious side effects requiring immediate medical attention include severe abdominal pain, vision changes, or signs of pancreatitis, though these occur rarely in clinical practice[3].

Why the 1.7mg Wegovy Price Represents Value in UK Weight Loss Treatment

The 1.7mg Wegovy price of £149.00 at Cured Pharmacy reflects genuine value when considered against the clinical evidence base and treatment outcomes. In the STEP 1 trial, 86.4% of participants receiving semaglutide achieved at least 5% weight loss, compared to 31.5% receiving placebo. Furthermore, 69.1% achieved at least 10% weight loss, and 50.5% achieved at least 15% weight loss, demonstrating clinically meaningful results across diverse patient populations[2].

Beyond the numerical weight loss data, Wegovy treatment in clinical trials improved cardiometabolic risk markers including blood pressure, lipid profiles, and glycaemic control in participants with prediabetes. These secondary benefits contribute to the overall health value proposition, potentially reducing long-term risks of cardiovascular disease, type 2 diabetes, and obesity-related complications. The 1.7mg dose forms an integral part of the titration pathway that enables patients to reach the therapeutic 2.4mg maintenance dose whilst minimising discontinuation due to side effects.

At Cured Pharmacy, we've structured our pricing to remove barriers to treatment access whilst maintaining the highest standards of pharmaceutical care. The £149.00 cost for 1.7mg Wegovy includes clinical expertise from our UK-registered prescribers, dispensing oversight by superintendent pharmacist Tarun Kumar, and the assurance of genuine MHRA-approved medication. New patients benefit from an additional £20 discount using code Weightlossnew, demonstrating our commitment to affordable access to evidence-based weight management treatments.

Maximising Results at the 1.7mg Wegovy Price Point

Achieving optimal outcomes from your investment in the 1.7mg Wegovy price requires combining medication with lifestyle modifications. Clinical trial participants in the STEP programme received counselling on reduced-calorie diet and increased physical activity, contributing to the impressive weight loss results observed. Whilst semaglutide reduces appetite and promotes satiety, conscious food choices and regular movement enhance treatment efficacy and support long-term weight maintenance[2].

Practical strategies include prioritising protein-rich foods to preserve lean muscle mass during weight loss, staying well-hydrated to manage potential gastrointestinal side effects, and establishing consistent meal timing to work synergistically with Wegovy's effects on gastric emptying. Many patients find that the appetite suppression at the 1.7mg dose makes it easier to adhere to portion control and resist high-calorie processed foods that previously challenged their weight management efforts.

As you approach the transition from 1.7mg to the 2.4mg maintenance dose, reflect on the behavioural changes you've established during the escalation phase. Sustainable weight loss extends beyond the pharmacological effects of semaglutide to encompass the habits and mindset shifts developed throughout your treatment journey. Our clinical team at Cured Pharmacy supports this holistic approach, recognising that the true value of the 1.7mg Wegovy price lies not just in the medication itself, but in the comprehensive pathway to healthier weight and improved metabolic health it facilitates.

When to Contact Your Prescriber During 1.7mg Treatment

Reach out to our clinical team if you experience persistent nausea lasting beyond the first few weeks at the 1.7mg dose, as this may indicate the need for additional anti-nausea strategies or a temporary pause in dose escalation. Similarly, contact us if you're not experiencing adequate appetite suppression or weight loss, as individual response to semaglutide varies and alternative treatments might prove more effective for your specific physiology. Our prescribers can adjust your treatment plan to optimise outcomes whilst managing the 1.7mg Wegovy price within your healthcare budget, ensuring you receive maximum clinical benefit from your investment in weight management therapy.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. [accessed 15 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.